Coronavirus (COVID-19)
Learn more
Phase I/II Trial of Bacillus Calmette-Guérin (BCG) and Intravesical Gemcitabine for Patients with BCG-Relapsing High-Grade Non-Muscle Invasive Bladder Cancer
This study will test the safety of BCG and gemcitabine in people who have BCG-relapsing Non-Muscle Invasive Bladder Cancer (NMIBC). The researchers will test increasing doses of gemcitabine to find the highest dose that causes few or mild side effects when combined with BCG. The study will also look at whether this combination of drugs is effective in treating BCG-relapsing NMIBC.
Eligibility Criteria:
This study is for patients age 18 and older.
Available at: Hartford Hospital, Hospital of Central Connecticut, Midstate Medical Center
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209